Regression of human coronary artery plaque is associated with a high ratio of (18‐hydroxy‐eicosapentaenoic acid + resolvin E1) to leukotriene B 4

Sex-mediated elevation of the specialized pro-resolving lipid mediator levels in a Sjögren's syndrome mouse model

(2020) Kaustubh Parashar et al.   FASEB JOURNAL

Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities

(2019) Magnus Bäck et al.   Nature Reviews Cardiology

An omega-3 fatty acid plasma index ≥4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment

(2019) Abdulhamied Alfaddagh et al.   ATHEROSCLEROSIS

ERV1/ChemR23 Signaling Protects from Atherosclerosis by Modifying oxLDL Uptake and Phagocytosis in Macrophages

(2018) Andres Laguna-Fernandez et al.   CIRCULATION

Resolvin E1 attenuates injury-induced vascular neointimal formation by inhibition of inflammatory responses and vascular smooth muscle cell migration

(2018) Guizhu Liu et al.   FASEB JOURNAL

Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators

(2018) Charles N. Serhan et al.   JOURNAL OF CLINICAL INVESTIGATION

Pro-resolving lipid mediators in vascular disease

(2018) Michael S. Conte et al.   JOURNAL OF CLINICAL INVESTIGATION

The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification

(2018) Miguel Carracedo et al.   CARDIOVASCULAR RESEARCH

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

(2018) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation

(2018) Paul C. Norris et al.   Scientific Reports

Opposing Effects on Vascular Smooth Muscle Cell Proliferation and Macrophage-induced Inflammation Reveal a Protective Role for the Proresolving Lipid Mediator Receptor ChemR23 in Intimal Hyperplasia

(2018) Gonzalo Artiach et al.   Frontiers in Pharmacology

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial

(2017) Abdulhamied Alfaddagh et al.   Journal of the American Heart Association

Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin

(2016) Kanita Salic et al.   ATHEROSCLEROSIS

Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice

(2016) Joana Viola et al.   CIRCULATION RESEARCH

Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling

(2016) Tarec K. Elajami et al.   FASEB JOURNAL

An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques

(2016) Gabrielle Fredman et al.   Nature Communications

Effect of Targeting Inflammation With Salsalate

(2016) Thomas H. Hauser et al.   JAMA Cardiology

Resolvin E1 (RvE1) Attenuates Atherosclerotic Plaque Formation in Diet and Inflammation-Induced Atherogenesis

(2015) H. Hasturk et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue

(2014) Romain A. Colas et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Inflammation and its Resolution as Determinants of Acute Coronary Syndromes

(2014) Peter Libby et al.   CIRCULATION RESEARCH

Pro-resolving lipid mediators are leads for resolution physiology

(2014) Charles N. Serhan   NATURE

The Pro-Resolving Lipid Mediator Maresin 1 (MaR1) Attenuates Inflammatory Signaling Pathways in Vascular Smooth Muscle and Endothelial Cells

(2014) Anuran Chatterjee et al.   PLoS One

Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities

(2013) I. Tabas et al.   SCIENCE

Comparison of coronary plaque subtypes in male and female patients using 320-row MDCTA

(2012) Faisal Khosa et al.   ATHEROSCLEROSIS

Role of Basic Science in the Development of New Medicines: Examples from the Eicosanoid Field

(2012) Bengt Samuelsson   JOURNAL OF BIOLOGICAL CHEMISTRY

Resolvin E2 Formation and Impact in Inflammation Resolution

(2012) S. F. Oh et al.   JOURNAL OF IMMUNOLOGY

Infection regulates pro-resolving mediators that lower antibiotic requirements

(2012) Nan Chiang et al.   NATURE

Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation

(2012) D. El Kebir et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution

(2011) Gabrielle Fredman et al.   BIOCHEMICAL JOURNAL

Lipoxygenase and Leukotriene Pathways: Biochemistry, Biology, and Roles in Disease

(2011) Jesper Z. Haeggström et al.   CHEMICAL REVIEWS

Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

(2011) Uchechukwu K. Sampson et al.   Current Atherosclerosis Reports

Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation

(2011) Sungwhan F. Oh et al.   JOURNAL OF CLINICAL INVESTIGATION

The immune system in atherosclerosis

(2011) Göran K Hansson et al.   NATURE IMMUNOLOGY

Clinical Predictors of Plaque Progression Despite Very Low Levels of Low-Density Lipoprotein Cholesterol

(2010) Ozgur Bayturan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Intravascular Ultrasound-Derived Measures of Coronary Atherosclerotic Plaque Burden and Clinical Outcome

(2010) Stephen J. Nicholls et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets

(2008) M. Dona et al.   BLOOD